125 related articles for article (PubMed ID: 2556398)
1. Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127.
Wardell MR; Weisgraber KH; Havekes LM; Rall SC
J Biol Chem; 1989 Dec; 264(35):21205-10. PubMed ID: 2556398
[TBL] [Abstract][Full Text] [Related]
2. The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity.
Dong LM; Innerarity TL; Arnold KS; Newhouse YM; Weisgraber KH
J Lipid Res; 1998 Jun; 39(6):1173-80. PubMed ID: 9643348
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia.
Havekes L; de Wit E; Leuven JG; Klasen E; Utermann G; Weber W; Beisiegel U
Hum Genet; 1986 Jun; 73(2):157-63. PubMed ID: 3721502
[TBL] [Abstract][Full Text] [Related]
4. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms.
Dong LM; Wilson C; Wardell MR; Simmons T; Mahley RW; Weisgraber KH; Agard DA
J Biol Chem; 1994 Sep; 269(35):22358-65. PubMed ID: 8071364
[TBL] [Abstract][Full Text] [Related]
5. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
Horie Y; Fazio S; Westerlund JR; Weisgraber KH; Rall SC
J Biol Chem; 1992 Jan; 267(3):1962-8. PubMed ID: 1730728
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
Wardell MR; Rall SC; Brennan SO; Nye ER; George PM; Janus ED; Weisgraber KH
J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112.
Weisgraber KH
J Lipid Res; 1990 Aug; 31(8):1503-11. PubMed ID: 2280190
[TBL] [Abstract][Full Text] [Related]
8. Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma.
Fazio S; Horie Y; Weisgraber KH; Havekes LM; Rall SC
J Lipid Res; 1993 Mar; 34(3):447-53. PubMed ID: 8468528
[TBL] [Abstract][Full Text] [Related]
9. Chylomicron remnant uptake in the livers of mice expressing human apolipoproteins E3, E2 (Arg158-->Cys), and E3-Leiden.
Lee SJ; Grosskopf I; Choi SY; Cooper AD
J Lipid Res; 2004 Dec; 45(12):2199-210. PubMed ID: 15466367
[TBL] [Abstract][Full Text] [Related]
10. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans.
Ji ZS; Fazio S; Lee YL; Mahley RW
J Biol Chem; 1994 Jan; 269(4):2764-72. PubMed ID: 8300609
[TBL] [Abstract][Full Text] [Related]
11. Identification of the disulfide-linked homodimer of apolipoprotein E3 in plasma. Impact on receptor binding activity.
Weisgraber KH; Shinto LH
J Biol Chem; 1991 Jun; 266(18):12029-34. PubMed ID: 2050696
[TBL] [Abstract][Full Text] [Related]
12. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia.
van den Maagdenberg AM; Hofker MH; Krimpenfort PJ; de Bruijn I; van Vlijmen B; van der Boom H; Havekes LM; Frants RR
J Biol Chem; 1993 May; 268(14):10540-5. PubMed ID: 7683682
[TBL] [Abstract][Full Text] [Related]
13. Structural variation in human apolipoprotein E3 and E4: secondary structure, tertiary structure, and size distribution.
Chou CY; Lin YL; Huang YC; Sheu SY; Lin TH; Tsay HJ; Chang GG; Shiao MS
Biophys J; 2005 Jan; 88(1):455-66. PubMed ID: 15475580
[TBL] [Abstract][Full Text] [Related]
14. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
van Dijk KW; van Vlijmen BJ; van der Zee A; van't Hof B; van der Boom H; Kobayashi K; Chan L; Havekes LM; Hofker MH
Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):7-12. PubMed ID: 9445249
[TBL] [Abstract][Full Text] [Related]
15. A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1.
Weisgraber KH; Rall SC; Innerarity TL; Mahley RW; Kuusi T; Ehnholm C
J Clin Invest; 1984 Apr; 73(4):1024-33. PubMed ID: 6323533
[TBL] [Abstract][Full Text] [Related]
16. Characterization of an apolipoprotein E3 variant (Arg 145-->His) associated with mild hypertriglyceridemia.
Hidaka H; Tozuka M; Hidaka E; Yamauchi K; Ota H; Honda T; Katsuyama T
Ann Clin Lab Sci; 2001 Apr; 31(2):163-70. PubMed ID: 11337906
[TBL] [Abstract][Full Text] [Related]
17. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
[TBL] [Abstract][Full Text] [Related]
18. Human low density lipoprotein receptor fragment. Successful refolding of a functionally active ligand-binding domain produced in Escherichia coli.
Simmons T; Newhouse YM; Arnold KS; Innerarity TL; Weisgraber KH
J Biol Chem; 1997 Oct; 272(41):25531-6. PubMed ID: 9325268
[TBL] [Abstract][Full Text] [Related]
19. Familial dysbetalipoproteinemia: a genetically heterogenous disease caused by mutations of the ligand apolipoprotein E.
Vermeer BJ; Frants RR; Havekes LM
J Invest Dermatol; 1992 Jun; 98(6 Suppl):57S-60S. PubMed ID: 1588125
[TBL] [Abstract][Full Text] [Related]
20. The receptor binding domain of apolipoprotein E is responsible for its antioxidant activity.
Pham T; Kodvawala A; Hui DY
Biochemistry; 2005 May; 44(20):7577-82. PubMed ID: 15896001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
